MK-677 raised IGF-1 and lean mass, not strength, in a year-long trial

Does MK-677 raise growth hormone and IGF-1?

MK-677 reliably raises growth hormone and IGF-1: every placebo-controlled study confirmed the hormonal effect, with IGF-1 rises of roughly 40 to 94% ^[1]⁠^[2]⁠^[3]⁠^[4].

The four placebo-controlled studies cited below include a pooled analysis of three trials ^[1]⁠^[2]⁠^[3]⁠^[4]. Each deserves a separate look, because pooling them into "the trials show it works" erases the distinction between what worked and what did not.

In the year-long trial in older adults, GH and IGF-1 normalized as expected ^[1]. In hip fracture patients, IGF-1 rose by 51.4 ng/ml (P<0.001) ^[2]. A pooled analysis of three trials in adults 65 and older found IGF-1 rises of 55 to 94% ^[3], and an 8-week trial in obese males found roughly 40% higher IGF-1 ^[4].

The pooled analysis also found higher bone turnover markers: osteocalcin up to 29.4% and bone-specific alkaline phosphatase up 10.4% (both P<0.001) ^[3]. MK-677 is pharmacologically active on the GH-bone axis, which is interesting for skeletal biology, but that analysis says nothing about strength, injury risk, or muscle performance.

How does MK-677 work?

MK-677 (ibutamoren) is a small, orally bioavailable, non-peptide molecule that binds the ghrelin receptor, GHS-R1a, the same receptor endogenous ghrelin activates.

MK-677 is not a peptide, despite sharing a shelf with GHRPs and GHRHs in most discussions. Ghrelin has two jobs in the body: it stimulates hunger, and it triggers pulsatile GH release from the pituitary. MK-677 does both, by design.

MK-677's half-life is long enough to raise GH pulse frequency and amplitude over a sustained 24-hour period, instead of the sharp single spike an injectable secretagogue produces. That sustained stimulation drives IGF-1, the downstream liver hormone that mediates most of GH's tissue effects, into a range that looks like a younger adult's baseline ^[1]⁠^[3]⁠^[4].

The mechanism is well characterized and not in dispute. What is underexamined is what that sustained GH and IGF-1 elevation buys the person taking it. For comparison, see macimorelin's diagnostic-only approval.

Does MK-677 build strength or improve function?

MK-677 did not improve strength or function in the year-long trial in older adults, and in hip fracture patients it improved only gait speed, marginally ^[1]⁠^[2].

In the longest study, 65 community-dwelling adults aged 60 to 81 took 25 mg/day for a full year. Fat-free mass rose by 1.1 kg, versus a 0.5 kg loss in the placebo group (P<0.001). Strength and functional measures, the outcomes that matter to daily life, did not improve ^[1].

In 123 elderly patients recovering from hip fracture, MK-0677 produced a marginal improvement in gait speed but failed most other functional measures ^[2]. The anamorelin results on lean mass and grip strength are reviewed separately.

Does MK-677 help with fat loss?

MK-677 did not reduce fat in its 8-week trial in obese males, the trial most relevant to anyone taking it to lean out ^[4].

That trial found the familiar pattern: roughly 40% higher IGF-1 and significantly increased fat-free mass on DEXA (P<0.01), but no reduction in total or visceral fat. Oral glucose tolerance was impaired ^[4].

Why was the MK-677 hip fracture trial stopped early?

The MK-0677 hip fracture trial was stopped early because of a congestive heart failure safety signal in the treatment arm ^[2].

The Phase IIb study had enrolled 123 elderly patients recovering from hip fracture ^[2]. Most write-ups bury it, yet it holds the most important safety data point in the MK-677 record. The heart failure signal is not a theoretical risk mentioned in a package insert; it is the specific reason a Phase IIb study did not finish as planned.

The signal occurred in a population with existing cardiovascular vulnerability tied to fracture recovery. Whether the same signal would appear in healthy young adults is unknown, and "unknown" is a different claim from "safe."

How strong is the evidence for MK-677?

MK-677's evidence rates grade C, moderate: the hormonal effect is well established, but the case for any real-world benefit is thin and comes with trial-documented downsides.

Four studies gave four confirmations of the hormonal effect and a consistent absence of the functional or compositional benefits people want. They also showed a consistent presence of metabolic costs, plus a cardiac cost in one trial.

MK-677 is not a compound where the evidence is absent. The evidence exists, and it does not say what most marketing implies. The growth hormone evidence on body composition and strength is a useful comparison.

What side effects does MK-677 cause?

Increased appetite is near-universal on MK-677 and expected from its mechanism ^[1]⁠^[4]. The appetite increase is the mechanism itself, not an incidental risk, because ghrelin's primary job is to stimulate hunger ^[1].

Water retention and edema, sometimes described as joint puffiness, showed up consistently enough to be a real consideration for anyone optimizing for visible muscle definition. It is not a rare complaint.

Elevated fasting glucose and worsened insulin sensitivity appeared in both trials that measured glucose tolerance directly ^[1]⁠^[4]. In the year-long trial, the worsening of insulin sensitivity was modest ^[1]. GH physiology antagonizes insulin action, so this is close to the expected pharmacology showing up as a lab value, not an occasional idiosyncratic reaction.

Lethargy, daytime drowsiness, and carpal-tunnel-like numbness or tingling are also reported, consistent with what other agents that meaningfully raise GH and IGF-1 produce. The appetite effect across ghrelin agonist trials is reviewed separately.

Is oral MK-677 safer than injectable growth hormone?

Oral MK-677 is not metabolically safer than injectable GH just because it is a pill; route of administration and metabolic consequence are separate questions ^[1]⁠^[4].

Being a pill has nothing to do with what elevated GH and IGF-1 do to insulin sensitivity or fluid balance. The trial data on those costs are as real for oral MK-677 as they would be for an injectable ^[1]⁠^[4].

What dose of MK-677 did the trials use?

Every cited MK-677 trial used 25 mg/day orally at night, and none of them compared doses to establish a minimum effective or optimal dose.

Forum convention runs 10 to 25 mg nightly, which overlaps the trial dose. Trial durations ran from 8 weeks ^[4] to 12 months ^[1]. No controlled human data extend beyond one year, so any claim about multi-year use is extrapolation, not evidence.

What is still unknown about MK-677?

No controlled MK-677 data exist in healthy young lifters or beyond a year, so the use most buyers plan sits outside the evidence:

• Healthy young users. Every cited RCT studied older adults, obese men, or hip fracture patients ^[1]⁠^[2]⁠^[3]⁠^[4]. Those populations and schedules do not establish the same outcomes in other age groups or in untested athletic use.
• Cardiac risk. The heart failure signal came from a fracture-recovery population with its own cardiovascular risk profile. Whether it generalizes to younger, healthier users is not established either way, and treating that absence of data as reassurance is a mistake.
• Long-term effects. No controlled trial has studied sustained IGF-1 elevation beyond 12 months, whether on cardiac tissue, insulin resistance trajectory, or cancer-related growth signaling, at any duration relevant to someone planning years of use.

MK-677 does one thing reproducibly: ghrelin receptor agonism that drives GH and IGF-1 upward. Whether that translates into anything a healthy person would call a benefit remains unconfirmed. The metabolic costs are repeatedly documented, and the cardiac cost in a vulnerable population is concrete.